Julie Maréchal-Jamil: Biosimilar Adalimumab in Europe

April 1, 2019

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes early experience with biosimilar adalimumab in Europe.

Transcript

What has been the impact of biosimilar adalimumab in the European marketplace?

For adalimumab, I think what’s worth highlighting—before we talk about the impact or anything, I think—for adalimumab, it’s a very unique situation. It’s something we’ve never seen before, and it’s rather unlikely that we’re going to see any such synchronicity in the launches.

For now, it’s still early days. We’re 3 months in. If you look at the overall European use of the adalimumab options, I think it’s probably been launched in half of the countries. In Germany, it’s been used to a higher extent over a shorter period than the previous biosimilars, showing greater confidence, greater acceptance.

It’s true that governments were very keen, and I think another unique feature of adalimuamb is not so much again the impact, but the way to the launches. While some governments have been preparing a lot for the lunches, the introduction of biosimilars, with adalimumab, it was extreme preparation. We’ve seen in the [United Kingdom] or Denmark really intense preparation, looking at all the features of the system that needed to be ready in time for the successful uptake, launches, introduction, and so on.